Stopping aspirin

PreclinicalSmall molecule

YYonsei University

Stopping aspirin is one of 3 small molecule programs targeting Antiplatelet Therapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Antiplatelet TherapyTerminated

Antiplatelet TherapyPreclinical

Terminated

Competition

Competitive Landscape

5 competitors in Antiplatelet Therapy

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Approved

9 2

Kengreal

Chiesi Farmaceutici S.p.A.

Approved

2 3

Stopping aspirin

YYonsei University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Antiplatelet Therapy1 trial

STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation

Terminated·YYonsei University·N/A·NCT03184805·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Stopping aspirin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Stopping aspirin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Stopping aspirin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYonsei University

Stopping aspirin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Antiplatelet Therapy1 trial

References

Drug Info

Quick Facts

Related News